Donnerstag 20. August 2026
https://www.gesund.at/eventberichte/prostatakarzinom-vernetzt-perspektiven-aus-drei-laendern/2330
Link kopieren
Ein länderübergreifender Austausch.
© Annie Spratt / unsplash.com
Das interdisziplinäre Webinar "Prostatakarzinom vernetzt" führte Ende Juni 2026 Expert:innen aus Deutschland, Österreich und der Schweiz zusammen. Es wurden zentrale Fragen der modernen Prostatakarzinomtherapie praxisnah erörtert – vom biochemischen Rezidiv bis hin zu dem oligometastasierten Stadium.
Inhaltsverzeichnis
Noch kein Benutzerkonto?
Jetzt kostenlos registrieren!
Ihre Vorteile:
Exklusive Fachbeiträge
DFP-Fortbildungen, jederzeit und von überall
Kongresskalender, alle Events auf einen Blick
Daily Doc Newsletter, täglich die wichtigsten News aus der Branche
Jetzt registrieren
Bereits registriert?
Loggen Sie sich hier ein
Artikel Info
Redakteur:in:
Erstellt am:
2. Juli 2026
Stand der medizinischen Information:
24. Juni 2026
Literatur
Freedland SJ et al., A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open. 2021 Aug 12;11(8):e046588.
Choudhury A et al., ASCO 2024: A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (A-DREAM/Alliance A032101)
Agarwal N et al., TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol. 2024 Mar;20(9):493-505.
Fizazi K, et al. A Phase 3 study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. ESMO Congress 2025.
De Bono JS et al. Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. ESMO Virtual Congress 2020, Abstract 610O
Clarke N et al., Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial European Urology Oncology, 2024; 8, 394-406
Agarwal N et al., Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial The Lancet, 2023; 402, 291-303
Chi KN et al., A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2025 Apr;21(9):1013-1031.
Vision: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) Morris M et al., 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024 Sep 28;404(10459):1227-1239.